Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 16, 2022; 10(29): 10467-10477
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10467
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10467
Table 1 Participant characteristics
Derivation cohort (n = 329) | Internal validation cohort (n = 164) | P | |
Age (yr), mean ± SD | 53.76 ± 11.64 | 57.38 ± 11.89 | 0.001a |
Male sex, n (%) | 253 (76.90) | 116 (70.70) | 0.137 |
Hospitalization period (d), mean ± SD | 8.40 ± 5.88 | 9.49 ± 4.69 | 0.026a |
Liver cirrhosis etiology, n (%) | |||
HBV | 220 (66.90) | 96 (58.50) | 0.07 |
HCV | 13 (3.95) | 6 (3.66) | 0.87 |
Alcoholic liver disease | 52 (15.80) | 30 (18.29) | 0.49 |
Schistosomiasis cirrhosis | 14 (4.25) | 8 (4.88) | 0.75 |
Primary biliary cirrhosis | 3 (0.90) | 5 (3.05) | 0.08 |
Cryptogenic cirrhosis | 27 (8.21) | 18 (11.00) | 0.31 |
Hospitalization reason, n (%) | |||
Variceal bleeding | 150 (45.60) | 76 (46.34) | 0.875 |
Hepatic encephalopathy | 86 (26.14) | 43 (26.22) | 0.985 |
Infection | 45 (13.68) | 21 (12.80) | 0.789 |
Ascites | 28 (8.50) | 13 (7.93) | 0.825 |
Hepatorenal syndrome | 20 (6.08) | 11 (6.71) | 0.787 |
Vasopressors | 88 (26.75) | 79 (48.17) | < 0.001a |
HBeAg (+) | 35 (10.64) | 15 (9.15) | 0.605 |
Mechanical ventilation | 18 (5.47) | 36 (21.95) | < 0.001a |
Biochemical parameters | |||
ALT, IU/L | 22.00 (16.00-40.75) | 29.00 (20.00-52.50) | < 0.001a |
AST, IU/L | 44.00 (31.00-90.50) | 39.00 (28.00-74.00) | 0.085 |
GGT, IU/L | 27.00 (15.00-74.50) | 29.00 (14.00-79.50) | 0.982 |
ALP, IU/L | 73.70 (55.00-112.00) | 82.50 (56.25-138.75) | 0.037a |
Serum sodium, mmol/L | 138.10 (135.00-141.00) | 137.85 (134.03-140.98) | 0.329 |
Creatinine, μmol/L | 72.70 (59.35-93.20) | 79.70 (63.55-115.00) | 0.006a |
INR | 1.32 (1.21-1.54) | 1.45 (1.24-1.74) | < 0.001a |
Bilirubin, μmol/L | 24.70 (15.80-42.80) | 26.85 (16.03-58.25) | 0.157 |
WBC, 10 × 9/L | 6.39 (3.94-9.61) | 6.81 (4.11-11.13) | 0.11 |
Platelet, 10 × 9/L | 74.50 (47.50-111.50) | 73.80 (39.00-109.50) | 0.245 |
PT, s | 15.00 (13.80-17.20) | 15.90 (13.40-19.20) | 0.086 |
MAP, mmHg | 83.00 (77.67-89.33) | 82.17 (78.00-87.67) | 0.472 |
PO2/FiO2 | 402.86 ± 118.57 | 388.28 ± 137.36 | 0.266 |
Albumin, g/L | 28.41 ± 7.87 | 27.64 ± 6.18 | 0.256 |
CTP score | 8 (7-10) | 9 (7-11) | 0.001a |
MELD score | 9.44 (5.96-13.52) | 12.20 (7.77-16.67) | < 0.001a |
Mortality, n (%) | |||
28 d | 41 (12.46) | 47 (28.66) | < 0.001a |
3 mo | 65 (19.76) | 69 (42.07) | < 0.001a |
6 mo | 75 (22.80) | 73 (44.51) | < 0.001a |
- Citation: Zhang W, Zhang Y, Liu Q, Nie Y, Zhu X. Development and validation of a prognostic nomogram for decompensated liver cirrhosis. World J Clin Cases 2022; 10(29): 10467-10477
- URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10467.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10467